Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Quizartinib Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.PHAR.646

    Clinical Policy: Quizartinib (Vanflyta)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.646 alerts

    Get alerted when Policy CP.PHAR.646 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity and prior-authorization coverage of quizartinib for adult members with AML or specified myeloid/lymphoid neoplasms, including initial and continued therapy. It applies to commercial, HIM/ICHRA, and Medicaid lines of business, subject to applicable state Medicaid provisions.

    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Quizartinib (Vanflyta)
    Policy CodePolicy CP.PHAR.646
    Change TypeRevision
    Effective DateDec 1, 2023
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation that the member meets all applicable initial- or continued-therapy criteria for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added single-agent quizartinib therapy for relapsed or refractory AML to the covered initial-therapy options.

    The policy added maintenance-therapy options after allogeneic hematopoietic cell transplantation and after prior FLT3-inhibitor therapy when no transplant is planned.

    The policy added off-label criteria for myeloid, lymphoid, or mixed-phenotype neoplasms with eosinophilia and FLT3 rearrangement.

    The AML initial approval duration was revised to 12 months.

    Continued-therapy criteria were revised to require current treatment for a covered indication rather than specifically referring only to AML.

    12 monthsApproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥18 years
    Minimum age
    FLT3-ITD/rearrangementRequired molecular finding
    2 tablets/dayMaximum quantity
    QT prolongationCardiac warnings
    17.7/26.5 mgTablet strengths

    Coverage Criteria

    Initial Therapy: Acute Myeloid Leukemia

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of acute myeloid leukemia (AML).
    • Prescribed by or in consultation with an oncologist or hematologist.
    • Member is age ≥ 18 years.
    • ONE of the following treatment pathways

      • Induction therapy in combination with cytarabine and an anthracycline (e.g., daunorubicin or idarubicin).
      • Consolidation therapy in combination with cytarabine.
      • Maintenance therapy as a single agent following ONE of the following

        • Consolidation chemotherapy.
        • Member is post-allogeneic hematopoietic cell transplantation and in remission.
        • Member previously received a FLT3 inhibitor (e.g., Rydapt or Xospata) and does not have an allogeneic hematopoietic cell transplantation planned.
      • Single-agent therapy for relapsed or refractory disease.
    • Presence of a FLT3 internal tandem duplication (ITD) mutation.
    • Member must use generic quizartinib, if available, unless contraindicated or clinically significant adverse effects are experienced.
    • ONE of the following dosing pathways

      • ALL of the following

        • Dose does not exceed 2 tablets per day.
        • ONE of the following FDA-approved dosing regimens

          • For induction therapy: 35.4 mg on days 8–21 for two 28-day cycles.
          • For consolidation therapy: 35.4 mg on days 6–19 for four 28-day cycles.
          • For maintenance monotherapy: 53 mg per day.
      • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

        Prescriber must submit supporting evidence.

    • The prescribed regimen must be FDA-approved or recommended by NCCN.

    Initial Therapy: Myeloid/Lymphoid Neoplasm (Off-Label)

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of myeloid/lymphoid or mixed phenotype neoplasms with eosinophilia in blast phase or chronic phase.
    • Prescribed by or in consultation with an oncologist or hematologist.
    • Member is age ≥ 18 years.
    • Presence of a FLT3 rearrangement.
    • Member must use generic quizartinib, if available, unless contraindicated or clinically significant adverse effects are experienced.

    Other Diagnoses/Indications

    Coverage is available when ONE of the following pathways applies:

    ONE of the following

    • Recent label change not yet reflected in this policy

      • The drug has recently, within the last 6 months, undergone a label change (e.g., a newly approved indication, age expansion, or new dosing regimen) that is not yet reflected in this policy.
      • Refer to the applicable policy based on formulary or PDL status

        • For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the no-coverage-criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
        • For drugs not on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.

    Continued Therapy: Other Diagnoses/Indications

    Coverage for continued therapy is available when ONE of the following pathways applies:

    ONE of the following

    • Recent label change not yet reflected in this policy

      • The drug has recently, within the last 6 months, undergone a label change (e.g., a newly approved indication, age expansion, or new dosing regimen) that is not yet reflected in this policy.
      • Refer to the applicable policy based on formulary or PDL status

        • For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the no-coverage-criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
        • For drugs not on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.

    Non-FDA-approved indications that are not addressed in this policy are not covered unless there is sufficient documentation of efficacy and safety in accordance with the applicable off-label use policy: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid, or applicable evidence of coverage documents.

    Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adults with newly diagnosed AML that is FLT3 ITD-positive as detected by an FDA-approved test.

    Vanflyta is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with Vanflyta in this setting has not been demonstrated.

    Dosing and Quantity Parameters

    Tablet quantity
    Maximum quantityDoes not exceed 2 tablets
    FrequencyPer day
    Continuation dose-increase limitA new dose must not exceed both 53 mg per day and 2 tablets per day unless supported for relevant off-label use
    Induction dosing
    Dose35.4 mg orally once daily
    ScheduleDays 8 through 21 of each cycle
    DurationTwo 28-day cycles

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Submit documentation showing that all applicable initial- or continued-therapy criteria are met, including the requested regimen and supporting clinical information. Approval duration is 12 months when criteria are satisfied.

    • Initial approval and continued-therapy requests require review against the applicable criteria.
    • Approval duration: 12 months.
    Step Therapy

    Generic Quizartinib Requirement

    Use generic quizartinib for Vanflyta requests when available. Brand Vanflyta may be considered only when generic quizartinib is contraindicated or the member experiences clinically significant adverse effects.

    • Document the contraindication or clinically significant adverse effects when generic quizartinib is not used.

    Clinical Background

    Quizartinib (Vanflyta) is a kinase inhibitor used for FLT3-mutated acute myeloid leukemia (AML). Its FDA-approved role is in combination with standard cytarabine and anthracycline induction, cytarabine consolidation, and subsequent maintenance monotherapy for adults with newly diagnosed FLT3-ITD-positive AML identified by an FDA-approved test.

    Key Terms

    AML
    AbbreviationAML
    DefinitionAcute myeloid leukemia
    FLT3
    AbbreviationFLT3
    DefinitionFMS-like tyrosine kinase 3
    ITD
    AbbreviationITD
    Definition

    Initial Therapy

    AML Initial Therapy

    Initial AML therapy must meet all listed criteria.

    AML initial therapy

    • Member has a diagnosis of AML.
    • Quizartinib is prescribed by or in consultation with an oncologist or hematologist.
    • Member is at least 18 years old.≥18 years
    • Member has a FLT3-ITD mutation.
    • Member uses generic quizartinib when available, unless contraindicated or clinically significant adverse effects are experienced.

    Continuation Therapy

    Continuation Therapy

    Continued therapy is covered when all criteria are met.

    Continuation

    • Current treatment requirement

      • Member is currently receiving the medication through the Centene benefit.
      • Documentation supports that the member is currently receiving Vanflyta for a covered indication and has received the medication for at least 30 days.≥30 days
    • Member is responding positively to therapy.
    • Member uses generic quizartinib when available, unless contraindicated or clinically significant adverse effects are experienced.

    Step Therapy Requirement

    StepRequirement
    1Use generic quizartinib when available, unless contraindicated or clinically significant adverse effects are experienced.

    Quantity Limit

    Quizartinib quantity limit
    MedicationQuizartinib
    Quantity limitNo more than 2 tablets
    FrequencyPer day
    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Quizartinib (Vanflyta)
    Policy CodePolicy CP.PHAR.646
    Change TypeRevision
    Effective DateDec 1, 2023
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation that the member meets all applicable initial- or continued-therapy criteria for prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaDosing and Quantity ParametersProvider Requirements and Denial RisksClinical BackgroundKey TermsInitial TherapyContinuation TherapyStep Therapy RequirementQuantity Limit
    Dose is within the FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

    Prescriber must submit supporting evidence.

  1. The prescribed regimen must be FDA-approved or recommended by NCCN.
  2. Requested use not specifically listed as non-covered

    • The requested use (e.g., diagnosis, age, or dosing regimen) is not specifically listed under Section III, Diagnoses/Indications for which coverage is NOT authorized.
    • The recent-label-change pathway above does not apply.
    • Refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
  3. Requested use not specifically listed as non-covered

    • The requested use (e.g., diagnosis, age, or dosing regimen) is not specifically listed under Section III, Diagnoses/Indications for which coverage is NOT authorized.
    • The recent-label-change pathway above does not apply.
    • Refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
  4. Consolidation dosing
    Dose35.4 mg orally once daily
    ScheduleDays 6 through 19 of each cycle
    DurationFour 28-day cycles
    Maintenance or continuation maximum
    Maximum dose53 mg per day
    Maintenance durationUp to thirty-six 28-day cycles
    AdministrationOrally once daily
    Maintenance QTcF threshold
    Dose escalation thresholdIncrease to 53 mg daily on day 15 of the first cycle only if QTcF is ≤ 450 ms
    Starting maintenance dose26.5 mg daily on days 1 through 14 of the first cycle when QTcF is ≤ 450 ms
    Dose-maintenance thresholdMaintain 26.5 mg daily if QTcF is > 500 ms
    Documentation Required

    Clinical Documentation Required

    The provider must submit clinical documentation supporting that the member meets all approval criteria, such as office chart notes, laboratory results, and other relevant clinical information.

    • Include supporting office notes, laboratory results, and other clinical information.
    Documentation Required

    Regimen and Dose Support

    Document the requested regimen and dose. Dosing that exceeds the stated limits or is used off label requires support from FDA-approved labeling, NCCN recommendations, practice guidelines, or peer-reviewed literature; the prescriber must submit the supporting evidence.

    • Initial AML dosing must not exceed 2 tablets and must match the applicable induction, consolidation, or maintenance parameters unless supported for relevant off-label use.
    • For continued therapy dose increases, the new dose must not exceed 53 mg per day and 2 tablets per day unless supported for relevant off-label use.
    • The prescribed regimen must be FDA-approved or recommended by NCCN.
    Documentation Required

    Diagnosis and Specialist Documentation

    Document the covered diagnosis, the member's age, specialist involvement, and the required molecular finding for the indication. Applicable requirements include adult age, oncology or hematology specialist prescribing or consultation, and FLT3 mutation or rearrangement status.

    • AML: diagnosis of acute myeloid leukemia, age 18 years or older, oncologist or hematologist involvement, and FLT3 ITD mutation.
    • Myeloid/lymphoid or mixed phenotype neoplasm with eosinophilia: blast or chronic phase, age 18 years or older, oncologist or hematologist involvement, and FLT3 rearrangement.

    Unsupported block type: denial_risk disallowed

    Denial Risk

    Unaddressed or Unsupported Indication

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy unless sufficient efficacy and safety documentation is submitted under the applicable off-label use policy or evidence of coverage requirements.

    • Unaddressed uses may require referral to the applicable formulary, non-formulary, or off-label policy.
    • Submit sufficient documentation of efficacy and safety for an unsupported off-label use.
    Denial Risk

    Cardiac or Electrolyte Contraindication

    Do not use quizartinib in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or a history of ventricular arrhythmias or torsades de pointes. Monitor for QT prolongation, torsades de pointes, and cardiac arrest risks.

    • Contraindications include severe hypokalemia and severe hypomagnesemia.
    • Contraindications include long QT syndrome and history of ventricular arrhythmias or torsades de pointes.
    • Boxed warnings include QT prolongation, torsades de pointes, and cardiac arrest.
    Denial Risk

    Failure of Continuation Criteria

    For continued therapy, document that the member is receiving the medication through the Centene benefit or has received Vanflyta for a covered indication for at least 30 days, is responding positively, and meets all applicable continuation and dose-increase requirements.

    • Document at least 30 days of therapy when applicable.
    • Document positive response to therapy.
    • For a dose increase, the new dose must not exceed 53 mg per day and 2 tablets per day unless supported by practice guidelines or peer-reviewed literature.
    • Approval duration: 12 months.
    Internal tandem duplication
    HSCT
    AbbreviationHSCT
    DefinitionHematopoietic stem cell transplantation
    QTcF
    AbbreviationQTcF
    DefinitionQT interval corrected by Fridericia's formula
    NCCN
    AbbreviationNCCN
    DefinitionNational Comprehensive Cancer Network
  5. Allowed treatment regimen

    • Induction therapy in combination with cytarabine and an anthracycline, such as daunorubicin or idarubicin.35.4 mg on days 8-21 for two 28-day cycles
    • Consolidation therapy in combination with cytarabine.35.4 mg on days 6-19 for four 28-day cycles
    • Maintenance monotherapy following consolidation chemotherapy.
    • Maintenance monotherapy after allogeneic hematopoietic cell transplantation when the member is in remission.
    • Maintenance monotherapy after prior FLT3-inhibitor therapy when no allogeneic hematopoietic cell transplantation is planned.
    • Single-agent therapy for relapsed or refractory disease.
  6. Dose requirement

    • The dose does not exceed 2 tablets per day and fits the specified induction, consolidation, or maintenance dosing.Maximum 2 tablets/day; maintenance 53 mg/day
    • The dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
  7. The prescribed regimen is FDA-approved or recommended by NCCN.
  8. Off-Label Initial Therapy

    Off-label myeloid/lymphoid neoplasm therapy must meet all listed criteria.

    Myeloid/lymphoid neoplasm initial therapy

    • Member has a myeloid, lymphoid, or mixed-phenotype neoplasm with eosinophilia in blast phase or chronic phase.
    • Quizartinib is prescribed by or in consultation with an oncologist or hematologist.
    • Member is at least 18 years old.≥18 years
    • Member has a FLT3 rearrangement.
    • Member uses generic quizartinib when available, unless contraindicated or clinically significant adverse effects are experienced.
    • Dose requirement

      • The dose is within the FDA maximum limit for any FDA-approved indication.
      • The dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
    • The prescribed regimen is FDA-approved or recommended by NCCN.
  9. Dose increase requirement

    • The new dose does not exceed 53 mg per day and 2 tablets per day.≤53 mg/day and ≤2 tablets/day
    • The new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
  10. The prescribed regimen is FDA-approved or recommended by NCCN.